CYTOSORB ,A NEW FILTER OF SEPSIS OR GROSS AND SEVERE INFECTION INVENTED AND MANUFACTURED IN INDIA: A GOOD HELP FOR SERIOUS PATIENTS

Bengaluru: India’s biotechnology major Biocon and US-based CytoSorbents on Friday announced that they have entered into a strategic partnership to start CytoSorb, a novel therapy for the management of sepsis.CytoSorb is a safe and effective extracorporeal cytokine filter, designed to target the prevention or treatment of organ failure, which is the cause of nearly half of all deaths in the intensive care unit.If left unchecked, ‘cytokine storm’ caused by excessive cytokine production can cause massive inflammation, organ failure and death in common life-threatening conditions such as sepsis, burn injury, trauma, lung injury ,multiple system organ failure ,crtically ill immunocompromised patients of TB,CANCER,IABETES AND HIV. Along with good ctical caring Antibiotics ,CytoSorb is a ‘first-in-class’ therapy that can provide an effective solution to physicians to treat critically ill patients suffering from sepsis.

Rakesh Bamzai, president marketing, Biocon, said, “CytoSorb is a safe and well-tolerated innovative therapy for managing cytokine storm in critically ill patients. Very high levels of cytokines are known to cause multiple organ failure, which is often life threatening. Through CytoSorb, we offer a promising treatment option to high risk patients in their fight against sepsis and other critical illnesses.”

Unlike any other previous approach, CytoSorb attacks sepsis from multiple angles — reducing cytokine storm, reducing many deadly bacterial toxins, and directing immune cells to target the infection while avoiding damage to otherwise healthy organs. When combined with Biocon’s critical care antibiotics, it is an ideal broad spectrum strategy to fight sepsis.

Severe sepsis and septic shock are major causes of morbidity and mortality worldwide. It is a leading cause of death in non-coronary ICUs and the 11th leading cause of death overall. Over a third of patients who develop sepsis die globally, even though the best standard of care is available.

In India, more than one million estimated new cases of severe sepsis are treated in the Indian ICUs each year, accounting for one out of every four patients in the ICU. According to a recent nationwide study of Indian Intensive Care Case Mix and Practice Patterns (INDICAPS) involving over 124 ICUs across 17 states in India, mortality was found to be as high as 46 per cent in patients with septic shock and 42.2 per cent overall in septic patients, compared with 17.8 per cent mortality for ICU patients who did not develop sepsis.
— with Shreya Nakipuria and 2 others.




Tags: biocon, criticall, cytosorb, drug, filter, for, ill, immune, new, patient, More…
Share